There is the potential for p53 and p16 staining to be complimentary, providing redundancy and improving accuracy when performed together to determine HPV status; this could overcome some or all of the challenges of using p16 as a single immunomarker, where both false positive and false negative results have been reported in HNSCC. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.